We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Slaps Second Impax Plant with a Form 483

FDA Slaps Second Impax Plant with a Form 483

August 15, 2014

Impax received its second Form 483 in less than a week for a poor inspection of its U.S. manufacturing facility, igniting fresh doubts on the company’s plan to win approval of its Parkinson’s drug Rytary.

The brand and generics drugmaker disclosed the citation issued July 31 to its Hayward, Calif., plant following a June to July inspection that uncovered quality violations such as failing to review batch problems. That notice came just days after the FDA slapped the company’s Taiwan plant with a separate Form 483 for failing to reject contaminated batches and properly validating equipment.

The FDA observed, for example, that Impax’s October 2012 laboratory report on release testing of a lot of pyridostigmine bromide tablets was out of specification (OOS). But the facility didn’t address the ramifications of generating the OOS result and whether it impacted other manufacturing operations, the FDA said.

Impax also was dinged for several repeat observations, such as failing to test whether generic products are equivalent to their branded counterpart. Several products lacked an equivalency assessment, including orphenadrine citrate ER tablets, bupropion HCl ER tablets, oxybutynin HCl ER and rimantadine HCl tablets, the agency said.

Another repeat observation centered on poor data integrity, an area receiving heightened scrutiny from the FDA. The plant has two spectrophotometers that don’t have adequate controls to ensure analysts can’t rewrite or delete analytical data. The systems are used in testing raw materials, stability and release.

Investigators also found a walk-in stability chamber in disrepair. The agency found rust stains on the metallic floor underneath rubber floor mats, a sagging ceiling tile and corrosion on a drain pan, according to the Form 483 with seven observations. The chamber is used to store products for stability studies.

Impax said that it is working to address the FDA’s latest observations and will respond to the agency in roughly two weeks. Impax did not return a request for comment as of press time.

It remains unclear how this latest development will impact the drugmaker’s hopes to get approval of its NDA for Rytary (IPX066). The drug was rejected by the FDA last year due to continuing problems at the Hayward plant. While Impax resubmitted the NDA, continuous delays in getting regulatory approval led to GlaxoSmithKline’s exit from a development and marketing partnership surrounding Rytary.

Don’t jeopardize your approvals with quality violations. Avoid manufacturing mistakes by purchasing Focus on GxPs: A DVD Training Toolkit for Your Most Common and Costly Manufacturing Mistakes.

Pharmaceuticals Quality GMPs Inspections and Audits Submissions and Approvals

Upcoming Events

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 17Feb

    Effective Auditing for Manufacturing Quality

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    Regeneron’s Antibody Cocktail Shows Efficacy as COVID-19 Treatment

  • Mobile apps client cellphone cell phone

    FDA to Review Berkshire’s 510(k) Submission for Remote Drug-Delivery System

  • COVID-19

    Desidustat Improves Oxygenation for Hospitalized COVID-19 Patients

  • abbott-logo.gif

    Abbott’s Panbio COVID-19 Test Gets Additional CE Marks

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing